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Abstract The human mineralocorticoid receptor of the steroid 
receptor family contains a modular structure with domain E 
which is considered to be a hormone binding domain. Recombi- 
nant protein approaches enabled us to clearly determine that this 
domain is also able to interact with F-actin (Kd about 2 ~M) and 
G-actin. Moreover, it was revealed that this mineralocorticoid 
receptor domain/actin interaction was modulated by specific 
mineralocorticoid ligands. Agonist (aldosterone) steroid binding 
almost totally (91%) abolished the interaction with F-actin, while 
antagonist (progesterone) binding allowed more than 30% of this 
binding. Steroid modulation of the interaction between domain E 
and actin indicated that this actin binding is specific and could be 
essential for cellular mineralocorticoid receptor activity. 
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1. Introduction 
The mineralocorticoid receptor (MR) belongs to the steroid 
receptor family. It contains ligand-activated transcription fac- 
tors that mediate specific gene expression [1]. The untrans- 
formed cytoplasmic MR is associated with a set of heat shock 
proteins (hsp) including hsp90 [2-5] and probably hsp70 [6], 
hsp56 [7] and p23 [8] as for other steroid receptors. After 
ligand binding, the receptor is translocated to the nucleus 
but the mechanism underlying this translocation is not yet 
known. 
One of the major constituants of the cytoplasmic proteins is 
actin, a highly conserved and ubiquitous protein. Actin mono- 
mers (globular actin or G-actin) are able to assemble in cells 
to form actin polymers (filamentous actin or F-actin). This 
assembly forms a highly dynamic actin cytoskeleton in most 
cells. 
It was previously shown that hsp90 was able to bind actin 
[9]. In addition, the ATPase domains of both hsp70 and actin 
have a common three-dimensional structure [10]. These two 
observations led us to investigate whether an interaction be- 
tween MR and actin could occur and further its regulation. 
As MR is poorly expressed naturally, we undertook our in- 
vestigation with the recombinant hormone binding domain 
(HBD or domain E) of the human mineralocorticoid receptor 
(hMR), shown to be the interaction domain between hMR 
and hsp90 [11]. Using co-sedimentation assays and ELISA 
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tests, we have shown that hMR directly interacts with actin in 
vitro through its HBD. Moreover, this interaction was modu- 
lated by the mineralocorticoid agonist and antagonist. Here 
we demonstrate that aldosterone (agonist) binding to the re- 
ceptor markedly destabilized the HBD/F-actin interaction, 
while progesterone (antagonist) binding allowed stronger in- 
teraction of the recombinant HBD with F-actin. 
2. Materials and methods 
2.1. Protein preparations 
Actin was purified from rabbit skeletal muscle as previously de- 
scribed [12] with slight modifications [13]. F-actin was stored at 4°C 
in buffer A (2 mM Tris-HC1 pH 8.0, 10 mM KC1, 0.1 mM CaC12 and 
1 mM NAN3). Preparation of G-actin was previously described [14]. F 
and G-actin were titrated by spectrophotometric measurement in a 
Kontron Uvikon 930 using actin e 1% at 280 nm = 1.1. Construction 
of plasmids encoding the HBD recombinant protein fused to the C- 
terminal part of the maltose binding protein (MBP) and its purifica- 
tion are described elsewhere [11]. Concentration of the fusion protein 
MBP-HBD was measured by the Bradford assay using BSA for cali- 
bration. HBD was separated from MBP by incubation of the purified 
MBP-HBD with Factor Xa for 120 min at room temperature. 
2.2. Co-sedimentation assays 
Co-sedimentations of F-actin with MBP-HBD were performed in 
an Airfuge (Beckman). 8 ktM of F-actin (i.e. 4 molar excess as the best 
conditions to demonstrate complete co-sedimentation f MBP-HBD 
by F-actin, Fig. 1A) was added to 2 laM of MBP-HBD. The mixture 
was incubated for 20 min at room temperature before centrifugation 
at 28 psi for 30 rain in a buffer containing 50 mM Tris HCI, pH 7.5, 
50 mM KC1, 0.1 mM CaCI2 and 1 mM NAN3. Control experiments 
consisted of sedimentation of MBP-HBD and F-actin alone. After 
centrifugation, the samples were analyzed as follows: the total mix- 
ture before co-sedimentation, the supernatant and pellet resuspended 
in the buffer described above were boiled in an equal amount of SDS 
loading buffer. The samples were then subjected to a 12% SDS-PAGE 
and visualized by Coomassie blue staining. Recombinant MBP-HBD 
was added to F-actin at different concentrations, asdescribed in Fig. 
2A. Densitometric analysis of the gels was performed. 
2.3. Gel electrophoresis and immunoblotting 
Proteins were separated by a 12% SDS-PAGE and transferred onto 
a nitrocellulose membrane (Bio-Rad). MBP was detected by 4E8 and 
HBD by 18C7, two monoclonal antibodies developed in our labora- 
tory. Monoclonal antibody fixation was revealed by a rabbit anti- 
mouse antibody coupled with alkaline phosphatase (from Jackson 
Immuno Research). 
2.4. Immunological techniques 
Binding of HBD recombinant proteins to actin was carried out 
using a solid-phase immunoassay (ELISA). 
100 I-tl/well of G-actin to a final concentration of 1 ~tM was ad- 
sorbed on microtiter plates overnight at 4°C. After rinses with PBS- 
Tween 0.1%o and PBS alone, saturation with 3% BSA in PBS was 
performed for 1 h at 37°C. Serially diluted recombinant MBP-HBD 
was then incubated in the wells for 1 h at 37°C. After rinses in PBS- 
Tween 0.1% and PBS alone, the wells were incubated with 50 ~tl of 
4E8 antibody (dilution 115). Following three rinses in PBS-Tween 
0.1% and one in PBS alone, the wells were incubated for 1 h at 
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37°C with 50/al of alkaline phosphatase conjugated anti-mouse sec- 
ondary antibody diluted to 1/5000 in PBS-5% dried milk. After three 
washes in PBS-Tween 0.1% and three other washes in NaCI 0.15 M, 
the wells were incubated for 1 h at 37°C in the presence of 100/al of 
para-nitrophenylphosphate (Sigma 104) diluted to 1 mg/ml in diethy- 
lethanolamine. 
2.5. Steroid binding experiments 
The purified MBP-HBD (about 400 nM concentration) was incu- 
bated for 90 min at 30°C with untreated reticulocyte lysate (Promega) 
fourfold diluted in TEGW buffer (10 mM Tris-HC1, pH 7.6, 1 mM 
EDTA, 20 mM sodium tungstate and 10% glycerol), supplemented 
with ATP and MgC12 to 1 mM with an ATP regenerating system 
consisting of 3 mM phosphocreatine (Sigma) and 5 units/ml of crea- 
tine phosphokinase (Sigma). 75/al samples were then incubated for 1 h 
with either [3H]aldosterone or [3H]progesterone at 100 nM concentra- 
tion, in the presence or absence of 50 laM of the radioinert steroid. 
Bound and free hormones were separated by centrifugation after prior 
incubation in a dextran/charcoal suspension (4% Norit/0.4% dextran). 
F-actin was then added at a final concentration of 4 ~tM and incu- 
bated for 20 rain at room temperature. After centrifugation at28 psi 
for 30 min, radioactivity from the pellet and the supernatant was 
counted in a Beckman spectrometer following the addition of 3 ml 
of scintillant fluid (Ultima Gold from Packard). The results are ex- 
pressed as a percentage of total radioactivity. 
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3. Results 
3.1. Binding of recombinant hMR with actin 
The recombinant hMR, consisting of hMR HBD (domain 
E corresponding to amino acids 729-984) fused to the maltose 
binding protein (MBP), was constructed and purified as de- 
scribed elsewhere [11]. The purified MBP-HBD protein (4 ~tM 
concentration) was analyzed after Airfuge centrifugation in 
the absence or presence of 16 txM F-actin. The Coomassie 
blue stained gel shown in Fig. 1A, lane 3, revealed that 
MBP-HBD interacted with F-actin. As a control, F-actin 
alone (Fig. 1A, lane 1) was completely pelleted whereas 
MBP-HBD, when centrifuged alone, totally remained in the 
supernatant (Fig. 1A, lane 2). This result revealed a direct 
interaction between MBP-HBD and F-actin. 
We used two monoclonal antibodies to characterize the 
specificity of the interaction, 18C7 which is HBD-specific, 
and 4E8 which is MBP-specific. HBD could be separated 
from MBP by digestion of the recombinant MBP-HBD with 
Factor Xa. MBP-HBD digested by Factor Xa (4 ~tM) was 
centrifuged with F-actin (20 ~tM). The sedimentation results 
were analyzed with the monoclonal antibodies 18C7 and 4E8 
(see Fig. 1B). As indicated in Fig. 1B on the right panel, MBP 
was not able to sediment with F-actin. In contrast, all of the 
HBD was recovered pelleted (Fig. 1B, left panel). These re- 
sults excluded any MBP-actin interaction and clearly revealed 
that the interaction was HBD-specific. 
We further characterized the interaction through a satura- 
tion analysis of the two proteins. Increasing concentrations of 
F-actin were added to a fixed concentration of MBP-HBD (4 
~tM). The total mixture, supernatant and pellet were analyzed 
by SDS-PAGE. Densitometric analyses of the Coomassie blue 
stained gels allowed quantitation of the pelleted recombinant 
protein, i.e. interacting with F-actin. From these data, a sa- 
turation curve was deduced, which is presented in Fig. 2A. 
The saturation curve highlighted the specificity of the interac- 
tion. Saturation was obtained for a MBP-HBD/F-act in molar 
ratio of about 1/7. The apparent Kd deduced from Fig. 2 was 
about 2 p.M. As a control, sedimentation of 4 ~tM MBP-HBD 
alone is shown in Fig. 2A (inset). The Coomassie blue stained 
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Fig. 1. Characterization of the MBP-HBD/F-actin interaction. A: 
Co-sedimentation assays between F-actin and the recombinant 
MBP-HBD protein. 8 /.tM of F-actin was sedimented alone (1), 
2/aM MBP-HBD was also sedimented alone (2) and 8 laM of F-ac- 
tin was co-sedimented with 2/aM MBP-HBD (3) after incubation as 
described in section 2. The samples corresponding to supernatants 
(S) and pellets (P) were boiled in an equal volume of SDS loading 
buffer and then electrophoresed on 12% SDS-PAGE before visuali- 
zation by Coomassie blue staining. B: Characterization f the inter- 
action specificity. 4/aM of MBP-HBD was digested with Factor Xa. 
16/aM of F-actin was added to the digestion volume. Co-sedimenta- 
tion assays with F-actin were performed as described in section 2. 
The nitrocellulose membrane, corresponding to the supernatant (S) 
and pellet (P), was incubated with fivefold diluted 18C7 (left panel), 
an anti-hMR HBD monoclonal antibody, or with fivefold diluted 
4E8, an anti-MBP monoclonal antibody (right panel). Monoclonal 
antibody fixation was revealed by a rabbit anti-mouse antibody 
coupled with alkaline phosphatase. 
gel revealed that MBP-HBD was not able to sediment alone 
at this concentration. 
As the glucocorticoids were shown to stabilize actin fila- 
ments [15] we investigated the possibility that MBP-HBD 
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would also interact with G-actin. G-actin was thus adsorbed 
on a microtiter plate at a constant concentration of 1 IxM. The 
interaction between increasing concentrations of MBP-HBD 
and coated G-actin was analyzed by ELISA technique, as 
described in section 2.4. Fig. 2B presents the saturation curve 
of G-actin with MBP-HBD. The curve profile presents a pla- 
teau, which reveals a specific interaction between MBP-HBD 
and G-actin. 
3.2. Ligand modulation of MBP-HBD/F-actin interaction 
To adopt a steroid binding conformation, MBP-HBD has 
to be associated with a set of hsp [12]. The purified recombi- 
nant protein was thus incubated in reticulocyte lysate, which 
is particularly rich in these different hsps. As mentioned in 
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Fig. 2. Saturation analyses of the actin/MBP-HBD interaction. A: 
Saturation analysis with F-actin. 4 IxM of MBP-HBD was incubated 
with increasing concentrations of F-actin (from 0.3 to 50 IxM). Incu- 
bation and preparation of the samples were as described in Fig. 1. 
Densitometric analysis of the gels was performed to quantify the 
Coomassie blue stained band. Inset: Sedimentation assay with only 
4 IxM HBD. The recombinant MBP-HBD was prepared in the usual 
buffer and then centrifuged as previously described. The samples in- 
dicated correspond to the total mixture before centrifugation (T), 
supernatant (S) and pellet (P). B: Saturation analysis with G-actin. 
G-actin was adsorbed on a microtiter plate at a constant concentra- 
tion of 1 p.M. Increasing concentrations of MBP-HBD were then 
added to interact with G-actin. The complex formed between the 
two components was measured by ELISA as described in section 2, 
using fivefold diluted 4E8, a monoclonal anti-MBP antibody. 
Monoclonal antibody fixation was revealed by an alkaline phospha- 
tase, conjugated anti-mouse secondary antibody. 
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Fig. 3. Ligand modulation of the MBP-HBD/F-actin interaction. A: 
Steroid binding experiments were performed as indicated in section 
2. Results were expressed as a percentage of the total radioactivity 
before centrifugation except for the direct interaction between MBP- 
HBD and F-actin measured in the absence of reticulocyte lysate 
where results are the expression of densitometric analysis of a Coo- 
massie blue stained gel. Results indicated were for the non-ligand 
bound MBP-HBD (cross-hatched bar), [3H]aldosterone-MBP-HBD 
complex (black bar) and [3H]progesterone-MBP-HBD complex 
(hatched bars). The data shown are the means + SE of three sepa- 
rate experiments. B: Dose-response investigation of the MBP-HBD/ 
F-actin interaction. Steroid binding experiments were performed as 
indicated in section 2 with increasing aldosterone and progesterone 
concentrations (from 1 nM up to 100 nM). The curves represent the 
radioactivity counted either in the supernatant (solid squares, with 
aldosterone; hollow squares, with progesterone) or the pellet (solid 
diamonds, with aldosterone; hollow diamonds, with progesterone). 
section 2.5, [ZH]aldosterone (MR agonist) or [3H]progesterone 
(MR antagonist) was then added to the mixture. As pre- 
viously described [11], the amount of receptor incubated in 
reticulocyte lysate is much greater than that actually able to 
bind steroids. We therefore could only study receptors able to 
bind [3H]steroids by measuring the radioactivity associated 
with such receptors. The ligand free receptor, in its oligomeric 
form, could not be investigated in these conditions. The 
[3H]steroid-MBP-HBD complex was co-sedimented with F- 
actin. As indicated in Fig. 3A, only about 9% of the total 
radioactivity was pelleted, indicating that the 
[3H]aldosterone-MBP-HBD complex co-sedimented poorly 
with F-actin. In contrast, the interaction between the 
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[3H]progesterone-MBP-HBD complex and F-actin was stron- 
ger because about 33% of the total radioactivity was pelleted. 
As a control, MBP-HBD without incubation in reticulocyte 
lysate almost totally co-sedimented with F-actin. This result 
clearly indicated that the interaction was specifically modu- 
lated by the mineralocorticoid l gands. In addition, the inter- 
action was probably not due to a distinct Kd of aldosterone or 
progesterone, since we have previously shown [11] that they 
had the same affinity for MBP-HBD. We also performed a
dose-response experiment (Fig. 3B) where, after incubation in 
reticulocyte lysate, increasing aldosterone and progesterone 
concentrations (from 1 to 100 nM) were added to a fixed F- 
actin concentration (4 ~tM). The results indicate saturable 
curves for both aldosterone and progesterone and for super- 
natants and pellets, strengthening the specificity of the inter- 
action. Moreover, the results obtained with the dose-response 
curves confirmed those obtained in Fig. 3A. Indeed, the 
curves demonstrated that the [3H]progesterone-MBP-HBD/ 
F-actin interaction is stronger than that of [3H]aldosterone- 
MBP-HBD/F-actin. 
4. Discussion 
In the present study, using a recombinant protein technique 
and taking advantage of the fact that the soluble construct of 
the mineralocorticoid receptor domain E can be specifically 
cleaved from the MBP part, we demonstrated that actin bind- 
ing is restricted to this domain of the hMR. Direct co-sedi- 
mentation assays between MBP-HBD and F-actin revealed a
Kd of 2 ktM for interactions. In addition, we determined that 
G-actin was also able to bind to hMR, as shown by ELISA 
techniques. Although a previous tudy showed that the gluco- 
corticoid receptor (GR), another member of the steroid recep- 
tor superfamily, bound actin filaments [16] via hsp90, we de- 
scribe here a direct interaction between a steroid receptor and 
actin. 
Our first results showed a non steroid-binding conforma- 
tion of the HBD. Indeed, in order to bind its ligands, MR has 
to be associated with a variety of proteins, particularly hsp90 
and probably hsp70, hsp56 and p23, as is the case for other 
members of the steroid family such as GR. We thus found 
that a 'nude' receptor could directly interact with F-actin. 
We also tried to determine whether ligand binding could 
regulate this interaction. MBP-HBD recovered a steroid bind- 
ing conformation through incubation in reticulocyte lysate 
[11]. In these conditions, the interaction was stronger with 
the [3H]progesterone-MBP-HBD complex than with 
[3H]aldosterone-MBP-HBD complex. The aldosterone-bound 
MR is widely described as being associated with hsp90 [2-5], 
as for the GR [17-19]. Furthermore, hsp90 was shown to be 
an actin binding protein [9,20,21]. Hsp90 also binds MR 
through its HBD [11], as for GR [22-24]. We suggest hat 
the hsp90-HBD association in the reticulocyte lysate masks 
the interaction site with F-actin. Progesterone, a mineralocor- 
ticoid antagonist, is thought to induce a conformational 
change of the receptor that differs from that induced by al- 
dosterone [25,26]. We thus propose that the better interaction 
observed between the [3H]progesterone-MBP-HBD complex 
and F-actin is due to the availability of the F-actin binding 
site. It was previously shown that progesterone binding in- 
duced a looser conformation of the ligand binding domain, 
contrary to aldosterone binding which induced a very tight 
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conformation of the binding structure able to withstand high 
protease concentrations [26]. The better interaction described 
with progesterone bound MBP-HBD could thus have been 
facilitated by the loose structure of the ligand binding domain, 
whereas the aldosterone-MBP-HBD structure was too tight to 
allow such an interaction with F-actin. Moreover, ligand 
modulation of the interaction revealed that hsp90 adopted a 
distinct conformation depending on whether it was associated 
with GR or MR. The direct interaction between hMR and F- 
actin cannot be extended to other steroid receptors. Indeed, 
GR interacts with F-actin via hsp90, while both progesterone 
[27,28] and estrogen receptors [29,30] are nuclear, and F-actin 
is mainly cytoplasmic. 
However, the role of the F-actin/steroid receptor interaction 
remains unclear. It was previously hypothesized [16,31] for 
GR that the hsp complex acted as a transport particle or 
transportosome for bidirectional shuttling of GR into and 
out of the nucleus. This shuttling could be modulated by 
interactions with F-actin. In the same way, shuttling of the 
receptor from the cytosol to the nucleus might be partly di- 
rected by actin and modulated by mineralocorticoid ligands, 
as seen above. Moreover, the affinity of F-actin for MBP- 
HBD was about 2 BM, which is the same affinity as hsp90 
for F-actin [20]. Both hsp90 and F-actin are widely repre- 
sented in the cytosol. The three proteins could therefore com- 
pete to interact. We hypothesize that F-actin is also an an- 
choring protein of the non-oligomeric form of the MR. 
Anchoring would then be regulated by hsp association and 
ligand binding with the receptor. 
Another protein, calmodulin, was observed to interact with 
the related GR [32]. This protein is thus a potential MR 
interacting protein and could modulate such interactions. In 
addition, many associations between actin and its interacting 
proteins are modulated by nucleotides. This remains to be 
investigated for the MR. 
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